BioVie (BIVI) director Sigmund Rogich granted 211,100 stock options

Rhea-AI Filing Summary

BioVie Inc. director Sigmund Rogich reported new option grants. On January 5, 2026, he was awarded stock options covering 70,000 shares and an additional 141,100 shares of BioVie common stock, each with an exercise price of $1.31 per share.

The 70,000-share option grant vests in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. For the 141,100-share grant, 75% vested on January 5, 2026, with the remaining options vesting in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROGICH SIGMUND

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		70,000		(1)	01/05/2031	Common Stock	70,000	$0	70,000	D
Stock Option (right to buy)	$1.31	01/05/2026		A		141,100		(2)	01/05/2031	Common Stock	141,100	$0	141,100	D

Explanation of Responses:

1. The options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.

2. 75% of the options vested on January 5, 2026 and the remainder of the options vest in three equal installments on January 5, 2027, January 5, 2028 and January 5, 2029.

	/s/ Joanne Wendy Kim, attorney-in-fact for Sigmund Rogich	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioVie (BIVI) disclose in this Form 4 filing?

BioVie reported that director Sigmund Rogich received two grants of stock options on January 5, 2026, covering a total of 211,100 shares of common stock.

How many stock options did BioVie director Sigmund Rogich receive?

Sigmund Rogich received 70,000 stock options in one grant and 141,100 stock options in a separate grant, for a combined total of 211,100 options.

What is the exercise price of the BioVie stock options granted to Sigmund Rogich?

Both stock option grants to Sigmund Rogich have an exercise price of $1.31 per share.

When do the 70,000 BioVie stock options granted to Sigmund Rogich vest?

The 70,000 options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the 2026 annual shareholders’ meeting.

What is the vesting schedule for the 141,100 BioVie stock options granted to Sigmund Rogich?

For the 141,100 options, 75% vested on January 5, 2026. The remaining options vest in three equal installments on January 5, 2027, January 5, 2028, and January 5, 2029.

Is Sigmund Rogich’s ownership in BioVie reported as direct or indirect?

The Form 4 lists the stock options as held with direct (D) ownership by Sigmund Rogich.